Nivolumab Plus Cabozantinib Tops Sunitinib for Renal Cell Carcinoma
Combination therapy superior with respect to progression-free, overall survival and overall response for first-line treatment of advanced RCC.
Combination therapy superior with respect to progression-free, overall survival and overall response for first-line treatment of advanced RCC.
New study data offer insight on the mechanisms of angiotensin converting enzyme 2 (ACE2) in clear cell renal cell carcinoma (ccRCC).
Researchers sought to determine accessibility and use of palliative care among patients with advanced renal cell carcinoma.
Todd Bauer, MD, presents updated data from a phase 1/2 study of the oral hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan.
Investigators studied whether sexual orientation affects screening for prevalent gender-specific cancers including prostate, breast, and cervical cancer.
Lythgoe et al studied patterns of race reporting in genitourinary (GU)
cancer trials.
A retrospective analysis evaluated the incidence of ONJ in patients who received VEGF-TKIs or immune-oncology therapy for mRCC and bone-targeted therapies for bone metastases.
A retrospective analysis sought to determine the effect of hypertension on overall survival, response, and progression-free survival in patients with mRCC.
A rise in neutrophil-to-lymphocyte ratio of 3 or more after 2 months of therapy is associated with an increased risk for death in less than 1 year and treatment failure in less than 6 months, according to investigators.
Choueiri et al tested the efficacy of the investigational hypoxia-inducible factor 2α (HIF-2α) inhibitor in combination with cabozantinib.